A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

Update Il y a 4 ans
Reference: EUCTR2008-006977-34

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To estimate antitumor activity of MLN8237 as measured by response rate in patients with AML and high-grade MDS


Inclusion criteria

  • Acute myelogenous leukemia (AML) and high-grade myelodysplastic syndrome (MDS)

Links